TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03550105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gentle Jogger
Description: Gentle Jogger is a passive simulated jogging device to be used 3 times per day for at least 30 mins for 7 days in this study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gentle Jogger
Description: Gentle Jogger is a passive simulated jogging device to be used 3 times per day for at least 30 mins for 7 days in this study
Study: NCT02704780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 2 regimes of misoprostol 400 microgram and 800 microgram injections used for 2 groups of women

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 2 regimes of misoprostol 400 microgram and 800 microgram injections used for 2 groups of women
Study: NCT03511443

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: hsRDT
Description: Testing highly sensitive RDT detection for low parasitemia
Study: NCT01175031

Intervention type: OTHER
Group type: OTHER
Intervention: Manipulation of Positive Airway Pressure (PAP)
Description: Positive airway pressure (PAP) will be manipulated throughout the night to induce breathing events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced , and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulation of Positive Airway Pressure (PAP)
Description: Positive airway pressure (PAP) will be manipulated throughout the night to induce breathing events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced , and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night.
Study: NCT00398996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Early versus intermediate versus late initiation of ART
Description: Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB therapy has been completed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Early versus intermediate versus late initiation of ART
Description: Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB therapy has been completed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Early versus intermediate versus late initiation of ART
Description: Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB therapy has been completed
Study: NCT03548649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exoskeleton robot training
Description: subjects will learn to independently use the exoskeleton robot to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
Study: NCT04319718

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MK-2048 High Eudragit Vaginal Film
Description: 2 x 2 vaginal film containing 30 mg of MK-2048 and either 68.1 mg of ammonio methacrylate copolymer type B (Eudragit®)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MK-2048 Low Eudragit Vaginal Film
Description: 2 x 2 vaginal film containing 30 mg of MK-2048 and 41.5 mg of ammonio methacrylate copolymer type B (Eudragit®)
Study: NCT02130583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Skills Training
Description: Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
Study: NCT01965470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Prevention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care
Study: NCT04948164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan 85mg and naproxen sodium 500mg
Description: Subjects took 1 tablet of the study drug (each containing sumatriptan 85mg and naproxen sodium 500mg) within 1h of an acute migraine attack of mild severity, and if the headache progressed to moderate severity within 2 hours, they could take the remedial drug phenol chai (each containing acetaminophen 500mg and caffeine 65mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects were given one tablet of placebo within 1 h of an acute migraine attack with mild severity, and if the headache progressed to moderate severity within 2 hours, they were given the remedial drug phenol chai (each tablet contains acetaminophen 500 mg and caffeine 65 mg).
Study: NCT03145636

Intervention type: DEVICE
Group type: OTHER
Intervention: vBloc Maestro Rechargeable System
Description: Intra-abdominal vagal blocking neuromodulation device for the treatment of obesity

Intervention type: DEVICE
Group type: OTHER
Intervention: vBloc Maestro Rechargeable System
Description: Intra-abdominal vagal blocking neuromodulation device for the treatment of obesity

Intervention type: DEVICE
Group type: OTHER
Intervention: vBloc Maestro Rechargeable System
Description: Intra-abdominal vagal blocking neuromodulation device for the treatment of obesity

Intervention type: OTHER
Group type: OTHER
Intervention: vBloc Achieve Weight Management Program
Description: Remotely accessible web-based program to add additional support to subjects with vBloc therapy

Intervention type: OTHER
Group type: OTHER
Intervention: vBloc Achieve Weight Management Program
Description: Remotely accessible web-based program to add additional support to subjects with vBloc therapy

Intervention type: OTHER
Group type: OTHER
Intervention: vBloc Achieve Weight Management Program
Description: Remotely accessible web-based program to add additional support to subjects with vBloc therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Control Weight Management (CWM) program
Description: In person visits with Registered Dietician, or trained staff who will counsel subjects on energy balance, dietary intake, physical activity and eating behavior modification.
Study: NCT02988024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005
Description: LY03005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pristiq
Study: NCT02516527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT00732550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single trocar cholecystectomy
Description: Patients with symptomatic cholelithiasis will be operated using the single trocar surgery approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard laparoscopic cholecystectomy
Description: Patients with symptomatic cholelithiasis will undergo a standard laparoscopic cholecystectomy
Study: NCT03688438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Incision Negative-Pressure Therapy
Description: A foam or gauze dressing is put directly on the wound. This foam acts as a filter to keep any large particles (such as blood clots or dead, sloughed off tissue) from clogging the vacuum system. A clear, occlusive, adhesive film covers and seals the dressing and wound, creating an airtight seal. A drainage tube leads from under the adhesive film and connects to a portable vacuum pump. This pump removes air pressure over the wound. The pump is programmed for strength of suction, amount of time it is to be applied and if it is to be intermittent or continuous. A chamber on the pump collects drainage and moisture is drawn away from the wound site.
Study: NCT04352387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Montessori Method for Dementia
Description: The Montessori Method highlights the importance of considering the past experiences, identifying interests and maximizing spared capacity and abilities of each individual.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Activities delivered regularly in the usual care, such as reading out newspapers, physical activities, and watching videos, in the 1-hour sessions.
Study: NCT01633411

Intervention type: DEVICE
Intervention: Focal Cryoballoon Ablation System - 6 seconds
Description: Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications.

Intervention type: DEVICE
Intervention: Focal Cryoballoon Ablation System - 8 seconds
Description: Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications.

Intervention type: DEVICE
Intervention: CryoBalloon Focal Ablation System - 10 seconds
Description: Ablation of Barrett's Esophagus using the Focal CryoBalloon Ablation System. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications.
Study: NCT05808192

Intervention type: DRUG
Intervention: Immunosuppressive
Description: compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.

Intervention type: DRUG
Intervention: Immunosuppressive
Description: compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.
Study: NCT02382991

Intervention type: DEVICE
Group type: OTHER
Intervention: NMPK-3C60
Description: 1 month with NMPK - 3 months with 3C60
Study: NCT02645032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT
Description: Manufacturer: SK Chemicals Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhim Vi®
Description: Manufacturer: Sanofi Pasteur Ingredient: Purified Vi-polysaccharide Appearance: colourless liquid Dose: 0.5mL/vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAXIGRIP®
Description: Dose: Single injection, participants 6-35 months of age will receive 0.25 ml (half a dose), participants 36 months of age and older will receive 0.5ml (full dose)~\*Participants less than 9 years of age, who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after the last follow-up visit of last participant in their age cohort.
Study: NCT00889850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
Description: 40 mg esomeprazole, single dose administration under fasted and fed condition
Study: NCT04183387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Study: NCT01374672

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00889850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INexium 40 mg MUPS tablets (AstraZeneca, France)
Description: 40 mg esomeprazole, oral single dose administration under fasted and fed condition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INexium 40 mg MUPS tablets (AstraZeneca, France)
Description: 40 mg esomeprazole, oral single dose administration under fasted and fed condition
Study: NCT03719963

Intervention type: DEVICE
Intervention: Cochlear implant
Description: Cochlear implant for hearing process by surgical intervention
Study: NCT03955328

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: A magnetic resonance imaging is perform to detect permanent anatomical damage.
Study: NCT04657185

Intervention type: OTHER
Intervention: OR PathTrac Feedback Optimization
Description: OR PathTrac (RDB Bioinformatics, Omaha, NE 68154) uses a systematic phenotypic approach leveraging temporal association to monitor 13 anesthesia work area reservoirs proven to be associated with high-risk intraoperative bacterial transmission events and subsequent infection development.
Study: NCT03336086

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: weight loss program
Description: A low calorie diet+ Orlistat+ Soluble Fiber+ Physical activity
Study: NCT02814838

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule
Study: NCT04294173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video education
Description: tracheostomy care will be given to student nurses with video training
Study: NCT02320968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MedclineTM Sleep Assist Pillow
Description: The pillow is designed so that the sleeper can have proper upper-body elevation while sleeping on his or her left side without the need for placing blocks under the head of the bed and bothering anyone else who may be sleeping in the bed. The pillow supports the patient's head, back and body to provide comfort while reducing or relieving acid reflux symptoms during sleep.
Study: NCT01992666

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Immunologic and genetic analysis from a single blood sample.
Study: NCT01708707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: The injectable formulation of buprenorphine (Buprenex; Reckitt Benckiser) will be prepared to a final concentration of 0.075 mg/mL in 100% ethanol and simple syrup USP to create a sublingual preparation.~Infants initial dose: 15.9 µg/kg per day in 3 divided doses with escalation/weaning based upon standardized scoring of NAS symptoms, using standardized Finnegan scoring Maximum dosage: 60 µg/kg per day Duration: Infants will receive buprenorphine until they are successfully weaned off of opioids and no longer show withdrawal symptoms, evidenced by low Finnegan scores. Mean use in other investigations was 24 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Oral Morphine Sulfate Dosage: Morphine Sulfate Oral Solution 100mg/5mL Initially dosed at 0.4mg/kg per day in six daily doses Duration of medication administration dependent upon infant symptoms of neonatal withdrawal, with mean duration of use at Banner Good Samaritan Hospital currently averaging 25 days.
Study: NCT02299648

Intervention type: OTHER
Group type: OTHER
Intervention: Molecular profiling
Description: molecular profiling, patient derived cells, fresh or FFPE
Study: NCT01676441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cellgram-spine
Description: Mesenchymal stem cells transplantation
Study: NCT00424346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03182413

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THN102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THN102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THN102
Study: NCT04575831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise, Nutrition, and Palliative Symptom Management
Description: 1. Exercise: The exercise intervention is a 12-week group-based program, with 1 weekly 75 minute session focused on strength, balance, flexibility and aerobic capacity.~2. Palliative Symptom Management: Palliative symptom management will focus on symptoms that contribute to reduced QOL, limit ability to engage in exercise, or present barriers to oral intake.~3. Nutrition: A Registered Dietitian (RD) team will provide feedback and tailored nutrition advice based on a pre-study food recall evaluation, recommending interventions based on the nutrition assessment feedback form, such as oral nutritional supplementation or target daily protein and caloric intake.
Study: NCT00868335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activ C disc prosthesis
Description: cervical disc prosthesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior cervical discectomy
Description: Removal of protruding cervical disc through an anterior approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy
Description: Removal of protruding cervical disc through an anterior approach
Study: NCT00795171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel * Sunitinib
Description: docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
Study: NCT02636192

Intervention type: DRUG
Intervention: No Intervention
Description: This is an observational study and participants did not receive any intervention in this study.

Intervention type: DRUG
Intervention: No Intervention
Description: This is an observational study and participants did not receive any intervention in this study.
Study: NCT00795171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: docetaxel 75mg/m2 day1 q 21d x 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 q21d for 4 cycles
Study: NCT01874119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fosaprepitant
Description: During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
Study: NCT03457740

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula 1
Description: Dietary supplement for strength, testosterone, sexual function, quality of life

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula 2
Description: Dietary supplement for strength, testosterone, sexual function, quality of life

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparison
Study: NCT00944216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salkera Emollient Foam
Description: application of the Salkera emollient foam twice a day during the 12 week study period.
Study: NCT04229108

Intervention type: DEVICE
Group type: OTHER
Intervention: Medopad
Description: Timed up and go module of Medopad application. About page explains how to perform test and conditions, subsequent page contains timer, once completed test, commence on final page which has a number of short questions to complete
Study: NCT04260438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T
Description: single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T
Description: single oral administration under fed condition
Study: NCT02671955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61610588
Description: Participants will receive intravenous infusions of JNJ-61610588 until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61610588
Description: Participants will receive intravenous infusions of JNJ-61610588 until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61610588
Description: Participants will receive intravenous infusions of JNJ-61610588 until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61610588
Description: Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
Study: NCT01039818

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radioiodine
Description: A unique dose of 200µCi of ¹³¹I/ml/24-RAIU

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioiodine
Description: A unique dose of 250µCi of ¹³¹I/ml/24-RAIU